Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good move!
My only chance at making real money is if we have a successful short squeeze during the recall of our loaned shares, and I am fortunate at getting filled on my sell orders. I may just bite the tax bullet so that my daughters won't have to worry about that. But I don't know yet what I'll do.
I opened a Roth IRA Yesterday. My hopes are that I can transfer 1 million shares of HGENQ from my E-Trade account into the IRA for when it appreciates that it will be tax free on those million shares. Plus knowing I can't touch it will keep me from selling it too early. :)
I love our double today even though it was only at .0004.
Yes, I think you have several accounts you manage for your family, with $50 sell prices. I hope the bid gets run up, and those orders fill, maybe with a premium price.
You go, Jay! I have several high-$ sell GTC orders myself. We shall see.
Some lucky Bastard in Canada got 100,000 shares at .0004! :)
Um...I didn't hear you. Can you say it again?
I've been curious about how management would time the upcoming events. Specifically, I wondered if management would begin to roll-out our immediate course change before or after the bankruptcy was concluded. Now we know.
Some years ago, I was disappointed that a number of prospective investors were denied purchases of shares because we were over-subscribed. I had hoped that management would accommodate them, which they did not do. But that was the right business decision at that time, just as concluding the bankruptcy before announcing new developments is the right business decision at this time.
I'm truly not concerned in the least bit. If short sellers were students of what this management team has done by capitalizing on the design of their share structure, they would have saved themselves the pending circumstance of being forced to buy-in their borrowed shares by submitting a bid to the bankruptcy judge. Now, however, I will be happy to provide shares at $200 for them to cover their short positions.
If Big Pharma deduced that Humanigen has created partnerships with Novavax and Gracell, and that we have a pathway to regulatory approval, even if initially overseas, they, too, would have submitted bids for the company. But Gilead's Daniel O'Day, and others, couldn't quite envision that, and will lose substantial market share in the near term, as a consequence.
Whoa I post that and the pps doubles
lol!
Hope you’re right, but no other bids doesn’t sound promising to me. I would be happy to be wrong about that!
I think our success is more of a sure shot, than a long shot. I think management anticipated events to unfold as they have, and they planned accordingly and brilliantly. All the pieces are coming together, and I hope that the results of management's efforts will prove life-changing for shareholders, and life-saving for future patients. I'm not surprised or worried about any of the developments we are seeing.
I always felt the lenz was effective. But when there is a sale for the company and no takers followed by a sale of the company assets and no takers, one has to believe the drug does not work and the data is suspect
Yep sounds like we are hosed if the judge hands Lenz over to Durant for $2 million.
I do appreciate Jays optimism since that seems like the only long shot chance that shareholders will benefit, but I don’t see that as Durrant doing it out of the kindness of his heart!
"In sum, the Stalking Horse Agreement is not just the highest
and best offer for the Acquired Assets, it is the only offer, and is the result of over a year of marketing efforts and months of independent and good-faith negotiations. The Sale to the Stalking Horse Bidder should be approved as a result"
https://document.epiq11.com/document/getdocumentbycode?docId=4292711&projectCode=HUM&source=DM
Back to HGEN….well there isn’t anything positive so I guess that’s why we are discussing immigration instead.
Investors are really sweet on Gracell, as we see a third Beneficial Ownership filing for them on Feb 14th, this one, "...subject to a Beneficial Ownership Blocker (as defined below)," which limited the acquisition to a total 9.99% stake in the company.
https://www.sec.gov/Archives/edgar/data/1346824/000110465924023999/tm246065d12_sc13ga.htm
Are these investors reacting to Gilead/Kite's announcement two weeks ago of FDA approval to "speed up" their CAR-T turnaround time from 16 days to 14 days?
https://www.fiercepharma.com/manufacturing/gileads-kite-wins-fda-nod-new-car-t-manufacturing-process-speed-yescarta-turnaround
This compares to Gracell's recently enhanced (with lenz?) "...FasT CAR solution, preparation time can be cut to 24 hours, significantly reducing production cost and waiting time."
https://www.pharmasources.com/industryinsights/54541.html
Almost as true as HGENQQQQQQ trading again. Insanity is an understatement
"In sum, the Stalking Horse Agreement is not just the highest
and best offer for the Acquired Assets, it is the only offer, and is the result of over a year of marketing efforts and months of independent and good-faith negotiations. The Sale to the Stalking Horse Bidder should be approved as a result"
https://document.epiq11.com/document/getdocumentbycode?docId=4292711&projectCode=HUM&source=DM
It appears that Dale may have dumped his Baudax shares. I'll continue monitoring the Baudax filings, in case we see Tera-Immune news.
https://www.sec.gov/Archives/edgar/data/1178179/000101359424000171/baudax13ga1-02142024.htm
I hate speaking about ethnicities, especially when my natural-born daughters are Amer-Asian. But we know one illegal Chinese-owned biolab has already been discovered operating in California. And I admit that I am concerned about this influx of illegal immigrants, and their objectives in coming here. I think it is in our national security interest to have lenz approved as a vaccine adjuvant, as well as a respiratory tract therapeutic.
appreciate. fingers and toes all crossed for any value. cheers to share holders.
Hi, Jim,
Welcome to the room, and to Ihub.
If Durrant had filed a Chapter 7 bankruptcy, shareholders would have been wiped out.
But Durrant filed a reorganization bankruptcy under Chapter 11, which allows for the share structure to remain intact.
Here are a couple of articles about our previous bankruptcy, when the company was known as Kalobios, before restructuring.
https://moxreports.com/kbio-infinity-squeeze/
https://www.globenewswire.com/news-release/2017/07/27/1063782/0/en/KaloBios-To-Change-Company-Name-To-Humanigen-Inc.html
I'm looking for management to recall their loaned shares once again, and to cause yet another massive short squeeze.
Isn't HGEN bankrupt? how do HGEN share holders have any chance at success? I was under impression that assets would be sold off and HGEN stock worth nothing now.
I'm not surprised by your comment. You have generally been more skeptical than I have been. But who hasn't been? It's been a tough road for shareholders.
But, it really is hard to comprehend the scope of our pending success. I understand that. It will be unparalleled. I've got faith in management, and in lenz. Even Ifab looks promising.
I just don't see a departure from the path management has been on since the company was established. I remain very optimistic and excited.
I’m thinking Durrant is taking his toys (Lenz) and leaving HGEN shareholders with a dirty playpen. Maybe the unsecured creditors claim will stop him from doing so and he will have to make better arrangements for the mess he has at HGEN?
Or he can take it all and walk away with “promises” under no legal obligation.
I think we are hosed.
You did miss something as we all did.
Maybe I missed somethings that you are aware of. Please show me, for example, why management has an obligation to discuss developments regarding Novavax.
Management HAS an obligation!! thats the disconnect
I track SEC filings everyday for Humanigen, Baudax, Gracell, and Novavax. That list was developed over the years for reasons I disclosed, as I thought each company represented an opportunity for Humanigen.
But those are my opinions. They do not place an obligation on management to comment. I am not a spokesman for the company. At best, I express what I think management may be doing, and I think they WILL comment on each of those companies as our transition continues.
This is pubic information. Why wouldn’t HGENQqqqqqq management keep shareholders updated on what they were doing? Because your theories are not true
Gracell sees a second amended 13G filed yesterday.
https://www.sec.gov/Archives/edgar/data/1826492/000121390024013387/ea193538-13ga1vivo_gracell.htm
Of course, the biggest bang for Durrant's drug development program dollars, isn't even mentioned in my earlier post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173802006
I have assumed that Novavax has been evaluating the use of lenz with their covid vaccine. Durrant may intend on integrating lenz with an anti-viral and polyclonal antibodies, in a fully developed cocktail, in accordance with our patent. A good amount of investment dollars seem to be flowing into Novavax now. How exciting!!
Two more amended 13G's filed today. One each for Gracell and Novavax.
https://www.sec.gov/cgi-bin/browse-edgar?company=gracell&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
https://www.sec.gov/Archives/edgar/data/102909/000110465924021584/tv01573-novavaxinc.htm
Durrant appears open to future discussions with unsecured creditors at a time and place TBD. I'm not worried about it way way or the other.
No other bidders…I don’t know man this ain’t looking so good for unsecured creditors imo. Hope I’m wrong
Recalling the loaned shares would force the buy-in of those borrowed shares. Additional shares can't be offered without diluting shareholders. I think our float is 229M shares, which is 192% of our OS.
Why would they recall shares, instead of offering for sale to keep the lights on? Where is the money coming from, not potential, real money? There is only 100m shares, that is nothing for a bio tech startup. Cydy has almost a billion.
No bids came in. Court hearing for the judge to approve the sale of HGENQ assets to Taran is February 14, 2024 at 1:30 p.m. ET. Judge will also hear the objections of the unsecured creditors to the sale Unsecured creditors filed an objection to the sale
Would be an absolute Dream Come True!
My ultimate hope, financially, is that management executes the recall of their loaned shares. It's exciting to see all the steps they are now taking, one after the other, to make this happen. I really don't see how the recall could be thwarted at this point.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173806573
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173782405
I think the recall of our loaned shares could be executed now.
But I don't think it will be. I think the recall will come with news that Humanigen could own between 89-92% of all Outstanding Shares. That degree of control has been long established.
And then, we get to new developments, potentially in regards to regulatory approval for CMML, with a possible PRV. Or news about partnerships, such as with Novavax, perhaps with an Advanced Purchase Agreement for the lenz/vaccine compound, and details about our Tera-Immune acquisition, or detail about a licensing agreement with Gracell. There's so much explosive potential! I'm looking forward to seeing it all!
I will most likely pull any sell orders that I have open if we come off the expert market? I only have some for sale now if the shorts want to cover at .40 cents.
This allows me to pay off my house and have some money left over to pay the taxes on the gain and have some left over to trade.
I am not asking for much. LOL :))
The other shares will remain at much higher prices.
In your fortunate situation, your opinion is easy to understand.
I would just be happy to see us come off the greys and trade again! .25 cents for starters would be really nice! :))
Who are the people in our neighborhood? We've seen recent beneficial ownership documents filed for both Baudax and Gracell. I can't wait to see how this helps Humanigen leverage our position with Tera-Immune and with CAR-T enhancement. We've got documented evidence of our interest in both companies.
But I'm most excited to see how a relationship may develop between Humanigen and Novavax, even though I have seen no evidence to believe that a specific relationship is being developed. I base my suspicion on our patented lenz/vaccine cocktail, and on what I perceive as unmet needs that the two companies can provide for each other. I'm super-excited at the prospect of a partnership being announced. And we have seen several beneficial ownership documents filed recently for Novavax, as well.
D***,
"D ⭐️⭐️⭐️
@_flyers77
What are the different options of how this can play out?"
https://twitter.com/_flyers77/status/1756752255309472232
The bankruptcy judge determined that the hearing established "... just cause for the relief granted herein; and any objections to the relief requested in the Motion having been withdrawn or overruled on the merits; and after due deliberation thereon and good and sufficient cause appearing therefor,
G. In the Motion and at the hearing on the relief set forth herein, the Debtor
demonstrated that good and sufficient notice of the relief granted by this Order has been given and
no further notice is required. A reasonable opportunity to object or be heard regarding the relief
granted by this Order has been afforded to those parties entitled to notice pursuant to Bankruptcy
Rule 2002 and all other interested parties.
H. The Debtor has articulated good and sufficient reasons for this Court to (i) approve
the Bid Procedures, (ii) schedule the bid deadlines and the Auction and the Sale Hearing,
(iii) approve the form and manner of notice of the Auction and Sale Hearing, (iv) approve
procedures for the assumption and assignment of the Contracts, including notice of the proposed
cure amounts, (v) authorize the Debtor to enter into the Stalking Horse Agreement, in the exercise
of its reasonable business judgment. The entry of this Order is in the best interests of the Debtor,
its estate, creditors, and other parties in interest."
pp 6,7,8/95
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1056710&projectCode=HUM&docketNumber=64&source=DM
So I don't see any red flags from the judge at this point, and I hope we can make it through tomorrow without any new bids.
"February 12, 2024 at 4:00 p.m. (Eastern): Deadline to submit Bid to be considered for the Auction.
February 13, 2024 at 4:00 p.m.: Sale Objection Deadline
February 13, 2024 at 10:00 a.m.: Auction (if necessary)
see pg 10/95
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1056710&projectCode=HUM&docketNumber=64&source=DM
Tomorrow could be a pivotal day for us. I hope things go as I expect, and that we may see additional news, as well. I think management has executed superbly.
Morgan Stanley today announced the acquisition of 7,281,646 shares of Novavax (6.2% stake).
https://www.sec.gov/Archives/edgar/data/1000694/000089542124000158/0000895421-24-000158-index.htm
Third beneficial ownership filing in about 5 weeks (State Street/SSGA and Blackrock).
https://www.sec.gov/Archives/edgar/data/1000694/000089542124000158/0000895421-24-000158-index.htm
Novavax has almost the same OS that Humanigen has, (Shares Outstanding 118.79M) and they are now trading at a 52 week low. I would love to see a stock-for-stock business combination or partnership with them. Huge potential. Look at their 5 year chart.
https://ih.advfn.com/stock-market/NASDAQ/novavax-NVAX/chart/real-time
Even if they only used the lenz vaccine cocktail for immuno-compromised and elderly patients, and even if that only popped our Market Cap to $8B, that could still be a sustained annual revenue of $67 per share for Humanigen.
Yes, I have a recognized, long-standing, pro-bias opinion toward Novavax. But we developed our patent for a reason, and this is the ideal application for that patent.
"METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20230109208
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: March 8, 2021
Publication date: April 6, 2023
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPELL
https://patents.justia.com/assignee/humanigen-inc
😁 🙂 That is where Jay's $200 per share comes in.
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43428
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |